BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Miner P, Orr W, Filippone J, Jokubaitis L, Sloan S. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am J Gastroenterol. 2002;97:1332-1339. [PMID: 12094846 DOI: 10.1111/j.1572-0241.2002.05769.x] [Cited by in Crossref: 106] [Cited by in F6Publishing: 105] [Article Influence: 5.6] [Reference Citation Analysis]
Number Citing Articles
1 Miwa H, Sasaki M, Furuta T, Koike T, Habu Y, Ito M, Fujiwara Y, Wada T, Nagahara A, Hongo M. Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan. Aliment Pharmacol Ther. 2007;26:69-77. [PMID: 17555423 DOI: 10.1111/j.1365-2036.2007.03350.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 4.1] [Reference Citation Analysis]
2 van Pinxteren B, Numans ME, Bonis PA, Lau J. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2006;:CD002095. [PMID: 16855986 DOI: 10.1002/14651858.CD002095.pub3] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
3 Ivashkin VT, Maev IV, Trukhmanov AS, Lapina TL, Storonova OA, Zayratyants OV, Dronova OB, Kucheryavyy YA, Pirogov SS, Sayfutdinov RG, Uspenskiy YP, Sheptulin AA, Andreev DN, Rumyantseva DE. Recommendations of the Russian Gastroenterological Association in Diagnosis and Treatment of Gastroesophageal Reflux Disease. Rossijskij žurnal gastroènterologii, gepatologii, koloproktologii 2020;30:70-97. [DOI: 10.22416/1382-4376-2020-30-4-70-97] [Cited by in Crossref: 17] [Cited by in F6Publishing: 1] [Article Influence: 17.0] [Reference Citation Analysis]
4 Sawada A, Fujiwara Y, Sifrim D. Belching in Gastroesophageal Reflux Disease: Literature Review. J Clin Med 2020;9:E3360. [PMID: 33092195 DOI: 10.3390/jcm9103360] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Baldwin CM, Keam SJ. Rabeprazole: a review of its use in the management of gastric acid-related diseases in adults. Drugs 2009;69:1373-401. [PMID: 19583455 DOI: 10.2165/00003495-200969100-00007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
6 Park CH, Kim HS, Lee SK. Effects of the New Prokinetic Agent DA-9701 Formulated With Corydalis Tuber and Pharbitis Seed in Patients With Minimal Change Esophagitis: A Bicenter, Randomized, Double Blind, Placebo-controlled Study. J Neurogastroenterol Motil 2014;20:338-46. [PMID: 24953714 DOI: 10.5056/jnm14019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
7 Sahara S, Sugimoto M, Uotani T, Ichikawa H, Yamade M, Iwaizumi M, Yamada T, Osawa S, Sugimoto K, Umemura K, Miyajima H, Furuta T. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole. Aliment Pharmacol Ther. 2013;38:1129-1137. [PMID: 24099474 DOI: 10.1111/apt.12492] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 4.5] [Reference Citation Analysis]
8 Goh K. "On-demand" therapy for gastroesophageal reflux disease: Are current proton pump inhibitors good candidates? J Gastroenterol Hepatol 2006;21:S115-8. [DOI: 10.1111/j.1440-1746.2006.04714.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
9 Tan VP, Wong WM, Cheung TK, Lai KC, Hung IF, Chan P, Pang R, Wong BC. Treatment of non-erosive reflux disease with a proton pump inhibitor in Chinese patients: a randomized controlled trial. J Gastroenterol 2011;46:906-12. [PMID: 21538030 DOI: 10.1007/s00535-011-0402-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
10 Johnson DA, Katz PO, Armstrong D, Cohen H, Delaney BC, Howden CW, Katelaris P, Tutuian RI, Castell DO. The Safety of Appropriate Use of Over-the-Counter Proton Pump Inhibitors: An Evidence-Based Review and Delphi Consensus. Drugs 2017;77:547-61. [PMID: 28233274 DOI: 10.1007/s40265-017-0712-6] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 8.8] [Reference Citation Analysis]
11 Fujiwara Y, Higuchi K, Nebiki H, Chono S, Uno H, Kitada K, Satoh H, Nakagawa K, Kobayashi K, Tominaga K. Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2005;21 Suppl 2:10-18. [PMID: 15943841 DOI: 10.1111/j.1365-2036.2005.02468.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
12 Hiyama T, Matsuo K, Urabe Y, Fukuhara T, Tanaka S, Yoshihara M, Haruma K, Chayama K. Meta-analysis used to identify factors associated with the effectiveness of proton pump inhibitors against non-erosive reflux disease. J Gastroenterol Hepatol. 2009;24:1326-1332. [PMID: 19702900 DOI: 10.1111/j.1440-1746.2009.05879.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
13 Maradey-Romero C, Kale H, Fass R. Nonmedical therapeutic strategies for nonerosive reflux disease. J Clin Gastroenterol. 2014;48:584-589. [PMID: 25000345 DOI: 10.1097/MCG.0000000000000125] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
14 Howden CW, Larsen LM, Perez MC, Palmer R, Atkinson SN. Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis - maintenance of healing and symptom relief. Aliment Pharmacol Ther 2009;30:895-907. [PMID: 19681809 DOI: 10.1111/j.1365-2036.2009.04119.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
15 Varannes SBD, Sacher-Huvelin S, Vavasseur F, Masliah C, Rhun ML, Aygalenq P, Bonnot-Marlier S, Lequeux Y, Galmiche JP. Rabeprazole test for the diagnosis of gastro-oesophageal reflux disease: Results of a study in a primary care setting. World J Gastroenterol 2006; 12(16): 2569-2573 [PMID: 16688803 DOI: 10.3748/wjg.v12.i16.2569] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
16 Sollano JD. Non-pharmacologic treatment strategies in gastroesophageal reflux disease. J Gastroenterol Hepatol 2004;19 Suppl 3:S44-8. [PMID: 15324381 DOI: 10.1111/j.1440-1746.2004.03593.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
17 Sugimoto M, Hasegawa T, Nishino M, Sahara S, Uotani T, Ichikawa H, Kagami T, Sugimoto K, Yamato Y, Togawa D, Kobayashi S, Hoshino H, Matsuyama Y, Furuta T. Improvement of gastroesophageal reflux disease in Japanese patients with spinal kyphotic deformity who underwent surgical spinal correction. Dig Endosc 2016;28:50-8. [PMID: 26331612 DOI: 10.1111/den.12543] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
18 van Pinxteren B, Sigterman KE, Bonis P, Lau J, Numans ME. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2010;CD002095. [PMID: 21069670 DOI: 10.1002/14651858.cd002095.pub4] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
19 Sultan N, Nazareno J, Gregor J. Association between proton pump inhibitors and respiratory infections: a systematic review and meta-analysis of clinical trials. Can J Gastroenterol 2008;22:761-6. [PMID: 18818790 DOI: 10.1155/2008/821385] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 4.2] [Reference Citation Analysis]
20 Dossett ML, Mu L, Davis RB, Bell IR, Lembo AJ, Kaptchuk TJ, Yeh GY. Patient-Provider Interactions Affect Symptoms in Gastroesophageal Reflux Disease: A Pilot Randomized, Double-Blind, Placebo-Controlled Trial. PLoS One 2015;10:e0136855. [PMID: 26422466 DOI: 10.1371/journal.pone.0136855] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
21 Shimatani T, Sugimoto M, Nishino M, Adachi K, Furuta K, Ito M, Kurosawa S, Manabe N, Mannen K, Hongo M, Chiba T, Kinoshita Y; the Acid-Related Symptom Research (ARS) Group. Predicting the efficacy of proton pump inhibitors in patients with non-erosive reflux disease before therapy using dual-channel 24-h esophageal pH monitoring: Intraesophageal 2-channel pH monitoring. Journal of Gastroenterology and Hepatology 2012;27:899-906. [DOI: 10.1111/j.1440-1746.2011.06975.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
22 Boparai V, Rajagopalan J, Triadafilopoulos G. Guide to the Use of Proton Pump Inhibitors in Adult Patients: . Drugs 2008;68:925-47. [DOI: 10.2165/00003495-200868070-00004] [Cited by in Crossref: 44] [Cited by in F6Publishing: 33] [Article Influence: 3.4] [Reference Citation Analysis]
23 Weijenborg PW, Cremonini F, Smout AJ, Bredenoord AJ. PPI therapy is equally effective in well-defined non-erosive reflux disease and in reflux esophagitis: a meta-analysis. Neurogastroenterol Motil. 2012;24:747-757, e350. [PMID: 22309489 DOI: 10.1111/j.1365-2982.2012.01888.x] [Cited by in Crossref: 88] [Cited by in F6Publishing: 76] [Article Influence: 9.8] [Reference Citation Analysis]
24 Kessing BF, Bredenoord AJ, Smout AJ. The pathophysiology, diagnosis and treatment of excessive belching symptoms. Am J Gastroenterol. 2014;109:1196-203); (Quiz) 1204. [PMID: 25001253 DOI: 10.1038/ajg.2014.165] [Cited by in Crossref: 47] [Cited by in F6Publishing: 32] [Article Influence: 6.7] [Reference Citation Analysis]
25 Shinozaki S, Osawa H, Hayashi Y, Sakamoto H, Miura Y, Lefor AK, Yamamoto H. Vonoprazan treatment improves gastrointestinal symptoms in patients with gastroesophageal reflux disease. Kaohsiung J Med Sci. 2017;33:616-622. [PMID: 29132551 DOI: 10.1016/j.kjms.2017.07.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
26 Chen CL, Hsu PI. Current advances in the diagnosis and treatment of nonerosive reflux disease. Gastroenterol Res Pract. 2013;2013:653989. [PMID: 23935610 DOI: 10.1155/2013/653989] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
27 Zad M, Bredenoord AJ. Chronic Burping and Belching. Curr Treat Options Gastroenterol 2020. [PMID: 31974815 DOI: 10.1007/s11938-020-00276-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Tytgat GN. Review article: management of mild and severe gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2003;17 Suppl 2:52-56. [PMID: 12786613 DOI: 10.1046/j.1365-2036.17.s2.5.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
29 Damiano A, Siddique R, Xu X, Johanson J, Sloan S. Reductions in symptom distress reported by patients with moderately severe, nonerosive gastroesophageal reflux disease treated with rabeprazole. Dig Dis Sci. 2003;48:657-662. [PMID: 12741452 DOI: 10.1023/a:1022812103923] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
30 de Boer W, de Wit N, Geldof H, Hazelhoff B, Bergmans P, Smout A, Tytgat G. Does Helicobacter pylori infection influence response rate or speed of symptom control in patients with gastroesophageal reflux disease treated with rabeprazole? Scand J Gastroenterol 2006;41:1147-54. [PMID: 16990199 DOI: 10.1080/00365520600741546] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
31 Quigley EM. New developments in the pathophysiology of gastro-oesophageal reflux disease (GERD): implications for patient management. Aliment Pharmacol Ther. 2003;17 Suppl 2:43-51. [PMID: 12786612 DOI: 10.1046/j.1365-2036.17.s2.14.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
32 Pallotta S, Pace F, Marelli S. Rabeprazole: a second-generation proton pump inhibitor in the treatment of acid-related disease. Expert Review of Gastroenterology & Hepatology 2014;2:509-22. [DOI: 10.1586/17474124.2.4.509] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
33 Joh T, Miwa H, Higuchi K, Shimatani T, Manabe N, Adachi K, Wada T, Sasaki M, Fujiwara Y, Hongo M. Validity of endoscopic classification of nonerosive reflux disease. J Gastroenterol. 2007;42:444-449. [PMID: 17671758 DOI: 10.1007/s00535-007-2022-3] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 2.8] [Reference Citation Analysis]
34 Pouchain D, Bigard MA, Liard F, Childs M, Decaudin A, McVey D. Gaviscon® vs. omeprazole in symptomatic treatment of moderate gastroesophageal reflux. a direct comparative randomised trial. BMC Gastroenterol 2012;12:18. [PMID: 22361121 DOI: 10.1186/1471-230X-12-18] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
35 Thjodleifsson B. Review of rabeprazole in the treatment of gastro-oesophageal reflux disease. Expert Opinion on Pharmacotherapy 2005;5:137-49. [DOI: 10.1517/14656566.5.1.137] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
36 Galmiche J. Endoscopy-negative reflux disease: part of the spectrum of non-steroidal anti-inflammatory drug or a separate disorder? Implications for treatment. Aliment Pharmacol Ther 2005;21:9-10. [DOI: 10.1111/j.1365-2036.2004.02348.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
37 Kinoshita Y, Ashida K, Hongo M; Japan Rabeprazole Study Group for NERD. Randomised clinical trial: a multicentre, double-blind, placebo-controlled study on the efficacy and safety of rabeprazole 5 mg or 10 mg once daily in patients with non-erosive reflux disease. Aliment Pharmacol Ther. 2011;33:213-224. [PMID: 21083596 DOI: 10.1111/j.1365-2036.2010.04508.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
38 Bruley des Varannes S, Gharib H, Bicheler V, Bost R, Bonaz B, Stanescu L, Delchier JC, Bonnot-Marlier S. Effect of low-dose rabeprazole and omeprazole on gastric acidity: results of a double blind, randomized, placebo-controlled, three-way crossover study in healthy subjects. Aliment Pharmacol Ther. 2004;20:899-907. [PMID: 15479362 DOI: 10.1111/j.1365-2036.2004.02176.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
39 Fass R, Johnson DA, Orr WC, Han C, Mody R, Stern KN, Pilmer BL, Perez MC. The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD. Am J Gastroenterol. 2011;106:421-431. [PMID: 21224838 DOI: 10.1038/ajg.2010.458] [Cited by in Crossref: 64] [Cited by in F6Publishing: 49] [Article Influence: 6.4] [Reference Citation Analysis]
40 Sigterman KE, van Pinxteren B, Bonis PA, Lau J, Numans ME. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2013;CD002095. [PMID: 23728637 DOI: 10.1002/14651858.cd002095.pub5] [Cited by in Crossref: 50] [Cited by in F6Publishing: 33] [Article Influence: 6.3] [Reference Citation Analysis]
41 Hershcovici T, Fass R. Nonerosive Reflux Disease (NERD) - An Update. J Neurogastroenterol Motil. 2010;16:8-21. [PMID: 20535321 DOI: 10.5056/jnm.2010.16.1.8] [Cited by in Crossref: 85] [Cited by in F6Publishing: 75] [Article Influence: 7.7] [Reference Citation Analysis]
42 Lim P, Goh K. Review Article: Efficacy and safety of rabeprazole in treating gastroesophageal reflux disease. J Gastroenterol Hepatol 2004;19:S61-8. [DOI: 10.1111/j.1440-1746.2004.03592.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
43 Bytzer P. Goals of therapy and guidelines for treatment success in symptomatic gastroesophageal reflux disease patients. Am J Gastroenterol 2003;98:S31-9. [PMID: 12644029 DOI: 10.1016/s0002-9270(03)00013-3] [Cited by in Crossref: 54] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
44 Orr WC. Therapeutic options in the treatment of nighttime gastroesophageal reflux. Digestion 2005;72:229-38. [PMID: 16319458 DOI: 10.1159/000089957] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
45 Fass R. Alternative therapeutic approaches to chronic proton pump inhibitor treatment. Clin Gastroenterol Hepatol. 2012;10:338-345; quiz e39-40. [PMID: 22178462 DOI: 10.1016/j.cgh.2011.12.020] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
46 Kushner PR, Peura DA. Review of proton pump inhibitors for the initial treatment of heartburn: is there a dose ceiling effect? Adv Ther 2011;28:367-88. [PMID: 21484335 DOI: 10.1007/s12325-011-0013-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
47 Furuta T, Shimatani T, Sugimoto M, Ishihara S, Fujiwara Y, Kusano M, Koike T, Hongo M, Chiba T, Kinoshita Y; Acid-Related Symptom Research Group. Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research Group in Japan. J Gastroenterol. 2011;46:1273-1283. [PMID: 21861141 DOI: 10.1007/s00535-011-0446-2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
48 Nocon M, Labenz J, Jaspersen D, Leodolter A, Meyer-sabellek W, Stolte M, Vieth M, Lind T, Malfertheiner P, Willich SN. Nighttime Heartburn in Patients with Gastroesophageal Reflux Disease under Routine Care. Digestion 2008;77:69-72. [DOI: 10.1159/000121372] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
49 Cook MB, Wild CP, Forman D. A systematic review and meta-analysis of the sex ratio for Barrett's esophagus, erosive reflux disease, and nonerosive reflux disease. Am J Epidemiol. 2005;162:1050-1061. [PMID: 16221805 DOI: 10.1093/aje/kwi325] [Cited by in Crossref: 149] [Cited by in F6Publishing: 130] [Article Influence: 9.3] [Reference Citation Analysis]
50 Fock K, Teo E, Ang T, Chua T, Ng T, Tan Y. Rabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease: A randomized, double-blind study in urban Asia. World J Gastroenterol 2005; 11(20): 3091-3098 [PMID: 15918196 DOI: 10.3748/wjg.v11.i20.3091] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 31] [Article Influence: 2.3] [Reference Citation Analysis]
51 Robinson M, Barone J. Review article: comparative pharmacodynamic review of rabeprazole - focus on day 1 data. Aliment Pharmacol Ther Symp Series 2006;2:315-26. [DOI: 10.1111/j.1746-6342.2006.00062.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
52 Kinoshita Y, Kazumori H, Ishihara S. Treatment of proton pump inhibitor-resistant patients with gastroesophageal reflux disease. J Gastroenterol 2006;41:286-7. [PMID: 16699865 DOI: 10.1007/s00535-006-1756-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
53 Wang Y, Yuan Y, Meng L, Fan H, Xu J, Zhang H, Wang M, Yuan H, Ou N, Zhang H, Chao Y, Shi R. Study of the pharmacokinetics and intragastric pH of rabeprazole given as successive intravenous infusion to healthy Chinese volunteers. Eur J Clin Pharmacol 2011;67:25-31. [PMID: 21110014 DOI: 10.1007/s00228-010-0949-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
54 Cohen H, Moraes-Filho JP, Cafferata ML, Tomasso G, Salis G, González O, Valenzuela J, Sharma P, Malfertheiner P, Armstrong D, Lundell L, Corti R, Sakai P, Ceconello I; Latin-American GORD Consensus Group. An evidence-based, Latin-American consensus on gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2006;18:349-68. [PMID: 16538106 DOI: 10.1097/00042737-200604000-00008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
55 Sugimoto M, Nishino M, Kodaira C, Yamade M, Uotani T, Ikuma M, Umemura K, Furuta T. Characteristics of non-erosive gastroesophageal reflux disease refractory to proton pump inhibitor therapy. World J Gastroenterol 2011; 17(14): 1858-1865 [PMID: 21528060 DOI: 10.3748/wjg.v17.i14.1858] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
56 Alecci U, Bonina F, Bonina A, Rizza L, Inferrera S, Mannucci C, Calapai G. Efficacy and Safety of a Natural Remedy for the Treatment of Gastroesophageal Reflux: A Double-Blinded Randomized-Controlled Study. Evid Based Complement Alternat Med 2016;2016:2581461. [PMID: 27818697 DOI: 10.1155/2016/2581461] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
57 Gerson LB, Bonafede M, Princic N, Gregory C, Farr A, Balu S. Development of a refractory gastro-oesophageal reflux score using an administrative claims database: Claims-based algorithm for refractory GERD. Alimentary Pharmacology & Therapeutics 2011;34:555-67. [DOI: 10.1111/j.1365-2036.2011.04755.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
58 Shan J, Oshima T, Chen X, Fukui H, Watari J, Miwa H. Trypsin impaired epithelial barrier function and induced IL-8 secretion through basolateral PAR-2: a lesson from a stratified squamous epithelial model. American Journal of Physiology-Gastrointestinal and Liver Physiology 2012;303:G1105-12. [DOI: 10.1152/ajpgi.00220.2012] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
59 Metz DC, Howden CW, Perez MC, Larsen L, O'Neil J, Atkinson SN. Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis. Aliment Pharmacol Ther 2009;29:742-54. [PMID: 19210298 DOI: 10.1111/j.1365-2036.2009.03954.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 3.8] [Reference Citation Analysis]
60 Savarino E, Zentilin P, Savarino V. NERD: an umbrella term including heterogeneous subpopulations. Nat Rev Gastroenterol Hepatol 2013;10:371-80. [DOI: 10.1038/nrgastro.2013.50] [Cited by in Crossref: 122] [Cited by in F6Publishing: 108] [Article Influence: 15.3] [Reference Citation Analysis]
61 Fass R. Erosive esophagitis and nonerosive reflux disease (NERD): comparison of epidemiologic, physiologic, and therapeutic characteristics. J Clin Gastroenterol. 2007;41:131-137. [PMID: 17245209 DOI: 10.1097/01.mcg.0000225631.07039.6d] [Cited by in Crossref: 169] [Cited by in F6Publishing: 150] [Article Influence: 12.1] [Reference Citation Analysis]
62 Kriengkirakul C, Patcharatrakul T, Gonlachanvit S. The Therapeutic and Diagnostic Value of 2-week High Dose Proton Pump Inhibitor Treatment in Overlapping Non-erosive Gastroesophageal Reflux Disease and Functional Dyspepsia Patients. J Neurogastroenterol Motil. 2012;18:174-180. [PMID: 22523726 DOI: 10.5056/jnm.2012.18.2.174] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
63 Cutler A, Robinson M, Murthy A, Delemos B. Rabeprazole 20 mg for Erosive Esophagitis-Associated Symptoms in a Large, Community-Based Study: Additional Results. Dig Dis Sci 2010;55:338-45. [DOI: 10.1007/s10620-009-0864-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
64 Maiti R, Jaida J, Israel PL, Koyagura N, Mukkisa S, Palani A. Rabeprazole and esomeprazole in mild-to-moderate erosive gastroesophageal reflux disease: A comparative study of efficacy and safety. J Pharmacol Pharmacother 2011;2:150-7. [PMID: 21897706 DOI: 10.4103/0976-500X.83278] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
65 CAG Clinical Affairs Committee. Community-acquired pneumonia and acid-suppressive drugs: position statement. Can J Gastroenterol 2006;20:119-21, 123-5. [PMID: 16482239 DOI: 10.1155/2006/324976] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
66 Bruley des Varannes S, Coron E, Galmiche JP. Short and long-term PPI treatment for GERD. Do we need more-potent anti-secretory drugs? Best Pract Res Clin Gastroenterol. 2010;24:905-921. [PMID: 21126703 DOI: 10.1016/j.bpg.2010.09.004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
67 Zhang JX, Ji MY, Song J, Lei HB, Qiu S, Wang J, Ai MH, Wang J, Lv XG, Yang ZR, Dong WG. Proton pump inhibitor for non-erosive reflux disease: A meta-analysis. World J Gastroenterol 2013; 19(45): 8408-8419 [PMID: 24363534 DOI: 10.3748/wjg.v19.i45.8408] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
68 Bytzer P, Blum A, De Herdt D, Dubois D. Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease. Aliment Pharmacol Ther. 2004;20:181-188. [PMID: 15233698 DOI: 10.1111/j.1365-2036.2004.01999.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 54] [Article Influence: 3.8] [Reference Citation Analysis]
69 hemmink GJM, weusten BLAM, bredenoord AJ, timmer R, smout AJPM. Increased swallowing frequency in GORD is likely to be caused by perception of reflux episodes. Neurogastroenterology & Motility 2009;21:143-8. [DOI: 10.1111/j.1365-2982.2008.01197.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
70 Mohanta D, Raha S, Vikram Gupta S, Ahmaruzzaman M. Bioinspired green synthesis of engineered CuSnO3 quantum dots: An effective material for superior photocatalytic degradation of Rabeprazole. Materials Letters 2019;240:193-6. [DOI: 10.1016/j.matlet.2018.12.104] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
71 Dadabhai A, Friedenberg FK. Rabeprazole: a pharmacologic and clinical review for acid-related disorders. Expert Opin Drug Saf 2009;8:119-26. [PMID: 19236223 DOI: 10.1517/14740330802622892] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
72 Chen CL, Liu TT, Yi CH. Disease progression in non-erosive reflux disease (NERD): impact of initial esophageal acid exposure. Dis Esophagus 2010;23:613-7. [PMID: 20545977 DOI: 10.1111/j.1442-2050.2010.01071.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
73 Fass R, Chey WD, Zakko SF, Andhivarothai N, Palmer RN, Perez MC, Atkinson SN. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease. Aliment Pharmacol Ther. 2009;29:1261-1272. [PMID: 19392864 DOI: 10.1111/j.1365-2036.2009.04013.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 56] [Article Influence: 5.3] [Reference Citation Analysis]
74 van Pinxteren B, Numans ME, Lau J, de Wit NJ, Hungin AP, Bonis PA. Short-term treatment of gastroesophageal reflux disease. J Gen Intern Med 2003;18:755-63. [PMID: 12950485 DOI: 10.1046/j.1525-1497.2003.20833.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
75 Takahashi M, Katayama Y. Reversal of the tolerance phenomenon by the intermittent administration of a histamine H2-receptor antagonist: Reversal of the tolerance phenomenon. Journal of Gastroenterology and Hepatology 2010;25:1493-7. [DOI: 10.1111/j.1440-1746.2010.06308.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
76 Akutagawa K, Iwakiri R, Hara M, Fujimoto K, Fujiwara Y, Inamori M, Tanaka J, Shimatani T, Akiyama J, Ando T, Manabe N, Kinjo F, Deguchi R, Kusano M. Risk factors for low response to proton-pump inhibitor treatment in reflux esophagitis and non-erosive reflux disease evaluated by the frequency scale for the symptoms of gastroesophageal reflux disease. Esophagus 2015;12:225-32. [DOI: 10.1007/s10388-014-0477-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Miner P. Review article: relief of symptoms in gastric acid-related diseases--correlation with acid suppression in rabeprazole treatment. Aliment Pharmacol Ther. 2004;20 Suppl 6:20-29. [PMID: 15496215 DOI: 10.1111/j.1365-2036.2004.02162.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
78 Fass R, Shapiro M, Dekel R, Sewell J. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease--where next? Aliment Pharmacol Ther. 2005;22:79-94. [PMID: 16011666 DOI: 10.1111/j.1365-2036.2005.02531.x] [Cited by in Crossref: 275] [Cited by in F6Publishing: 249] [Article Influence: 17.2] [Reference Citation Analysis]
79 Robinson M. Proton pump inhibitors: update on their role in acid-related gastrointestinal diseases. Int J Clin Pract. 2005;59:709-715. [PMID: 15924600 DOI: 10.1111/j.1368-5031.2005.00517.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 48] [Article Influence: 3.9] [Reference Citation Analysis]
80 Sharma P, Shaheen NJ, Perez MC, Pilmer BL, Lee M, Atkinson SN, Peura D. Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation--results from two randomized controlled studies. Aliment Pharmacol Ther. 2009;29:731-741. [PMID: 19183157 DOI: 10.1111/j.1365-2036.2009.03933.x] [Cited by in Crossref: 81] [Cited by in F6Publishing: 64] [Article Influence: 7.4] [Reference Citation Analysis]
81 Gerson LB, Kahrilas PJ, Fass R. Insights into gastroesophageal reflux disease-associated dyspeptic symptoms. Clin Gastroenterol Hepatol 2011;9:824-33. [PMID: 21699806 DOI: 10.1016/j.cgh.2011.05.015] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 4.8] [Reference Citation Analysis]
82 An X, Zhang B, Li X, Du T, Ai Z, Zhang C, Xu J, Sun F, Zhang Y, Du Y. Construction of 4-(Methylthio)isochromenones Skeleton through Regioselective Intramolecular Cyclization of 2-Alkynylbenzoate Mediated by DMSO/[D 6 ]DMSO and SOCl 2: Construction of 4-(Methylthio)isochromenones Skeleton through Regioselective Intramolecular Cyclization of 2-Alkynylbenzoate Mediated by DMSO/[D6]DMSO. Eur J Org Chem 2020;2020:852-9. [DOI: 10.1002/ejoc.201901723] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 7.0] [Reference Citation Analysis]
83 Hewitson P, Glasziou P, Irwig L, Towler B, Watson E. Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database Syst Rev. 2007;CD001216. [PMID: 17253456 DOI: 10.1002/14651858] [Cited by in Crossref: 2625] [Cited by in F6Publishing: 769] [Article Influence: 187.5] [Reference Citation Analysis]
84 Sloan S. Rabeprazole-based therapy in the management of symptomatic gastroesophageal reflux disease. Am J Gastroenterol 2003;98:S49-55. [PMID: 12644031 DOI: 10.1016/s0002-9270(03)00015-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
85 DeVault KR. Review article: the role of acid suppression in patients with non-erosive reflux disease or functional heartburn. Aliment Pharmacol Ther. 2006;23 Suppl 1:33-39. [PMID: 16483268 DOI: 10.1111/j.1365-2036.2006.02798.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
86 van Pinxteren B, Numans M, Bonis P, Lau J, Numans M. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 1996. [DOI: 10.1002/14651858.cd002095.pub2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
87 Miyasaka M, Hirakawa M, Nakamura K, Tanaka F, Mimori K, Mori M, Honda H. The endoscopic diagnosis of nonerosive reflux disease using flexible spectral imaging color enhancement image: a feasibility trial: Endoscopic diagnosis of NERD using FICE. Diseases of the Esophagus 2011;24:395-400. [DOI: 10.1111/j.1442-2050.2010.01166.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
88 de Souza Pereira R. Regression of gastroesophageal reflux disease symptoms using dietary supplementation with melatonin, vitamins and aminoacids: comparison with omeprazole. J Pineal Res. 2006;41:195-200. [PMID: 16948779 DOI: 10.1111/j.1600-079x.2006.00359.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
89 Ong AM, Chua LT, Khor CJ, Asokkumar R, s/o Namasivayam V, Wang Y. Diaphragmatic Breathing Reduces Belching and Proton Pump Inhibitor Refractory Gastroesophageal Reflux Symptoms. Clinical Gastroenterology and Hepatology 2018;16:407-416.e2. [DOI: 10.1016/j.cgh.2017.10.038] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 8.3] [Reference Citation Analysis]
90 Kahrilas PJ, Miner P, Johanson J, Mao L, Jokubaitis L, Sloan S. Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease. Dig Dis Sci. 2005;50:2009-2018. [PMID: 16240208 DOI: 10.1007/s10620-005-3000-3] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 2.2] [Reference Citation Analysis]
91 Armstrong D, Talley NJ, Lauritsen K, Moum B, Lind T, Tunturi-Hihnala H, Venables T, Green J, Bigard MA, Mössner J. The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole. Aliment Pharmacol Ther. 2004;20:413-421. [PMID: 15298635 DOI: 10.1111/j.1365-2036.2004.02085.x] [Cited by in Crossref: 68] [Cited by in F6Publishing: 53] [Article Influence: 4.0] [Reference Citation Analysis]
92 Orlando RC, Liu S, Illueca M. Relationship between esomeprazole dose and timing to heartburn resolution in selected patients with gastroesophageal reflux disease. Clin Exp Gastroenterol 2010;3:117-25. [PMID: 21694855 DOI: 10.2147/CEG.S12333] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
93 Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. Drugs 2003;63:2739-54. [PMID: 14664653 DOI: 10.2165/00003495-200363240-00004] [Cited by in Crossref: 117] [Cited by in F6Publishing: 102] [Article Influence: 6.9] [Reference Citation Analysis]
94 Ichikawa H, Sugimoto M, Sugimoto K, Andoh A, Furuta T. Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis. J Gastroenterol Hepatol 2016;31:716-26. [PMID: 26580676 DOI: 10.1111/jgh.13233] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 4.6] [Reference Citation Analysis]
95 Cremonini F, Ziogas DC, Chang HY, Kokkotou E, Kelley JM, Conboy L, Kaptchuk TJ, Lembo AJ. Meta-analysis: the effects of placebo treatment on gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2010;32:29-42. [PMID: 20353496 DOI: 10.1111/j.1365-2036.2010.04315.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 3.3] [Reference Citation Analysis]
96 Bytzer P. Assessment of reflux symptom severity: methodological options and their attributes. Gut. 2004;53 Suppl 4:iv28-iv34. [PMID: 15082611 DOI: 10.1136/gut.2003.034298] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
97 Kobeissy AA, Hashash JG, Jamali FR, Skoury AM, Haddad R, El-Samad S, Ladki R, Aswad R, Soweid AM. A randomized open-label trial of on-demand rabeprazole vs ranitidine for patients with non-erosive reflux disease. World J Gastroenterol 2012; 18(19): 2390-2395 [PMID: 22654431 DOI: 10.3748/wjg.v18.i19.2390] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
98 de Korwin J, Ducrotté P, Vallot T. Les nouveaux inhibiteurs de la pompe à protons, un progrès dans la prise en charge des maladies acido-peptiques ? La Presse Médicale 2004;33:746-54. [DOI: 10.1016/s0755-4982(04)98731-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
99 Ashida K, Kinoshita Y, Hongo M; The Japan Rabeprazole Study Group for NERD. Acid-Suppressive Effect of Rabeprazole 5 mg and 10 mg Once Daily by 24-Hour Esophageal pH Monitoring in Patients with Non-erosive Reflux Disease in Japan: A Multicenter, Randomized, Parallel-Group, Double-Blind Pharmacodynamic Study. Dig Dis Sci 2011;56:2333-42. [DOI: 10.1007/s10620-011-1583-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
100 Cheung TK, Wong BC. Proton-pump inhibitor failure/resistance: Proposed mechanisms and therapeutic algorithm. J Gastroenterol Hepatol 2006;21:S119-24. [DOI: 10.1111/j.1440-1746.2006.04716.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
101 Irani S, Krevsky B, Desipio J, Kim-jaffe J, Maqbool S, Fisher RS. Rapid protection of the gastroduodenal mucosa against aspirin-induced damage by rabeprazole: PROTECTION OF THE GASTRODUODENAL MUCOSA FROM ASA. Alimentary Pharmacology & Therapeutics 2008;27:498-503. [DOI: 10.1111/j.1365-2036.2008.03600.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
102 Bruley des Varannes S. The proton-pump inhibitor test: pros and cons. Eur J Gastroenterol Hepatol. 2004;16:847-852. [PMID: 15316406 DOI: 10.1097/00042737-200409000-00005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
103 Robinson M. Review article: the pharmacodynamics and pharmacokinetics of proton pump inhibitors--overview and clinical implications. Aliment Pharmacol Ther. 2004;20 Suppl 6:1-10. [PMID: 15496213 DOI: 10.1111/j.1365-2036.2004.02160.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 3.2] [Reference Citation Analysis]
104 Chey WD. Endoscopy-negative reflux disease: concepts and clinical practice. Am J Med 2004;117 Suppl 5A:36S-43S. [PMID: 15478851 DOI: 10.1016/j.amjmed.2004.07.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 13] [Article Influence: 0.2] [Reference Citation Analysis]
105 Chen L, Chen Y, Li B. The efficacy and safety of proton-pump inhibitors in treating patients with non-erosive reflux disease: a network meta-analysis. Sci Rep 2016;6:32126. [PMID: 27581096 DOI: 10.1038/srep32126] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.6] [Reference Citation Analysis]